Gufic Biosciences Ltd.

•

guficbio.comBSE: 509079NSE: GUFICBIO

Market Cap₹ 4,408 Cr.

Current Price

High / Low₹ 468 / 268

Stock P/E60.0

Book Value₹ 69

Price to Book4.14

Dividend Yield0.02 %

ROCE12.6 %

ROE10.1 %

Face Value₹ 1

Add ratio to table

ABOUT

AI Sector View

AI GENERATED

Healthcare

Buy

This stance relies on proxies and positioning because no direct pharma-export or healthcare operating series exists in the dataset. The depreciated currency at 95.23 (Sep/26) can support export earnings, inflation at 4.45% (Jul/26) is manageable for a defensive sector, and consumer spending remains large at INR 44743 billion (Jun/26). Strong FPI inflow of INR 10620 crore over 3 months to 2026-08-31 from INR -11381 crore in the prior 3 months adds a real sector-specific tailwind, but confidence stays capped because the fundamental drivers are indirect proxies.

Confidence

50%

View full sector analysis →

PROS

Latest quarter profit grew 70.7% YoY, showing strong momentum
Company generates healthy free cash flow

CONS

Though reporting repeated profits, the company pays out little dividend (1.6%)

* The pros and cons are machine generated based on quantitative rules.

Peer comparison

HealthcareHealthcarePharmaceuticals & Drugs

Part ofNIFTY 50 NIFTY 500 NIFTY LARGEMIDCAP 250 NIFTY 100 NIFTY 200

S.No.	Name
1.	SUNPHARMA	1881.10	37.31	451338.90	0.85	29012.30	1165.33	152998.80	1004.57	19.11	28.81
2.	DIVISLAB	9570.55	86.86	254068.03	0.31	902.00	65.50	3080.00	27.80	21.51	40.75
3.	TORNTPHARM	4962.75	86.55	188767.06	0.77	566.00	3.28	4921.00	57.32	19.27	33.81
4.	ZYDUSLIFE	1150.00	25.42	114712.94	0.09	990.20	-34.90	8017.00	23.97	21.39	24.54
5.	CIPLA	1383.95	33.17	111803.57	0.94	785.55	-39.18	7119.28	4.13	16.00	16.73
6.	LAURUSLABS	1945.50	96.14	105117.74	0.10	362.07	123.94	2026.31	29.10	18.20	31.50
7.	AUROPHARMA	1686.00	26.13	97008.71	0.24	1032.03	25.22	9150.35	17.44	12.76	20.54
8.	LUPIN	2112.00	17.47	96574.55	0.85	1416.98	16.01	8276.89	34.28	28.86	29.59
9.	DRREDDY	1151.50	29.83	96113.39	0.69	435.60	-69.10	8099.80	-5.21	13.75	10.63
10.	MANKIND	2305.85	46.63	95242.00	0.04	574.09	29.12	4030.59	12.89	13.24	26.30
11.	GLENMARK	2477.35	38.89	69916.93	0.10	482.83	927.88	4018.48	31.35	20.35	20.03
12.	GUFICBIO	439.55	60.01	4407.92	0.02	22.31	70.72	260.82	16.58	12.56	17.87

Detailed Comparison with:

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	215	202	195	203	204	208	205	224	237	231	252	261
	176	165	161	167	166	174	179	190	199	198	205	231
Operating Profit	39	36	34	36	39	34	26	33	38	33	47	30
OPM %	18.32%	18.07%	17.55%	17.64%	18.91%	16.32%	12.86%	14.88%	15.96%	14.25%	18.75%	11.34%
	0	0	1	1	0	2	0	1	2	1	-1	0
Interest	4	3	4	5	5	5	8	9	10	8	9	9
Depreciation	4	4	4	4	4	5	8	8	8	8	8	8
Profit before Tax	31	30	27	28	29	26	11	17	23	18	29	30
Tax %	25.01%	24.70%	26.07%	25.79%	25.61%	26.50%	26.69%	24.32%	25.58%	29.91%	24.35%	25.72%
Net Profit	0	0	0	21	22	19	8	13	17	12	22	22
	2.39	2.23	2.00	2.08	2.17	1.93	0.77	1.30	1.68	1.24	2.18	2.22

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

	Mar 2024	Mar 2025	Mar 2026	TTM
	807	820	944	981
	659	684	793	833
Operating Profit	147	136	151	148
OPM %	18.26%	16.60%	16.03%	15.05%
	2	4	3	2
Interest	17	25	37	37
Depreciation	17	21	31	31
Profit before Tax	116	94	87	99
Tax %	25.53%	26.02%	25.81%	26.04%
Net Profit	86	70	64	73
EPS	8.59	6.95	6.40	—
Dividend Payout %	1.16%	1.44%	1.56%	—

COMPOUNDED SALES GROWTH

10 Years:: —
5 Years:: —
3 Years:: —

COMPOUNDED PROFIT GROWTH

10 Years:: —
5 Years:: —
3 Years:: —

STOCK PRICE CAGR

10 Years:: 27%
5 Years:: 17%
3 Years:: 13%
1 Year:: 16%

RETURN ON EQUITY

10 Years:: —
5 Years:: —
3 Years:: 13%
Last Year:: 10%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

	Mar 2024	Mar 2025	Mar 2026
Equity Capital	10	10	10
	523	591	655
	313	310	379
Trade Payables	166	159	199
	81	100	99
Total Liabilities	1,093	1,169	1,342
	159	506	491
Capital Work in Progress	307	22	22
	2	2	2
	200	217	324
	330	315	297
Cash & Bank	13	29	76
	81	79	129
Total Assets	1,093	1,169	1,342

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

	Mar 2024	Mar 2025	Mar 2026
	-7	123	45
Cash from Investing	-102	-71	-31
Cash from Financing	82	-37	32
	-27	15	46

Ratios

Consolidated Figures in Rs. Crores / View Standalone

	Mar 2024	Mar 2025	Mar 2026

Shareholding Pattern

Numbers in percentages

	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	72.50	72.51	72.51	72.51	72.52	72.50	72.50	72.50	72.50
	0.23	0.23	0.30	0.31	0.32	0.33	0.44	0.42	0.47
	2.38	2.51	2.99	3.39	3.38	3.66	3.74	3.83	3.67
Government	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	24.88	24.74	24.21	23.79	23.78	23.51	23.32	23.25	23.36

Documents

Corporate disclosures, annual reports, credit ratings, and concall transcripts

2026-09-08

Credit Rating

2026-09-08 - Gufic Biosciences Limited has informed the Exchange about Credit Rating

2026-09-07

Shareholders meeting

2026-09-07 - Gufic Biosciences Limited has submitted the Exchange a copy of Scrutinizers report and voting results of 42nd Annual General Meeting held on September 04, 2026

2026-09-04

Shareholders meeting

2026-09-04 - Gufic Biosciences Limited has informed the Exchange regarding Proceedings of 42nd Annual General Meeting held on September 04, 2026

2026-09-02

General Updates

2026-09-02 - Gufic Biosciences Limited has informed the Exchange about Promotion and Change in Designation of Senior Management Personnel

2026-08-21

Analysts/Institutional Investor Meet/Con. Call Updates

2026-08-21 - Gufic Biosciences Limited has informed the Exchange about Transcript

2026-08-18

Copy of Newspaper Publication

2026-08-18 - Gufic Biosciences Limited has informed the Exchange about Copy of Newspaper Advertisement regarding Special Window for Re-lodgement of Transfer and Dematerialization of Physical Shares

2026-08-17

Analysts/Institutional Investor Meet/Con. Call Updates

2026-08-17 - Gufic Biosciences Limited has informed the Exchange about Link of Recording

2026-08-15

Copy of Newspaper Publication

2026-08-15 - Gufic Biosciences Limited has informed the Exchange about Copy of Newspaper Advertisement of Unaudited Financial Results (Standalone and Consolidated) for the quarter ended June 30, 2026

2026-08-14

General Updates

2026-08-14 - Gufic Biosciences Limited has submitted to the Exchange the Investor Presentation for the quarter ended June 30, 2026

News

Recent coverage and analyst commentary for GUFICBIO

Loading news…

🤖

AI Stock Analyst

Gufic Biosciences Ltd.

🔒

Sign in to Chat with AI

✨ Sign In to Chat

Free 5nance Account

Name

SUNPHARMA

1881.10

37.31

451338.90

0.85

29012.30

1165.33

152998.80

1004.57

19.11

28.81

DIVISLAB

9570.55

86.86

254068.03

0.31

902.00

65.50

3080.00

27.80

21.51

40.75

TORNTPHARM

4962.75

86.55

188767.06

0.77

566.00

3.28

4921.00

57.32

19.27

33.81

ZYDUSLIFE

1150.00

25.42

114712.94

0.09

990.20

-34.90

8017.00

23.97

21.39

24.54

CIPLA

1383.95

33.17

111803.57

0.94

785.55

-39.18

7119.28

4.13

16.00

16.73

LAURUSLABS

1945.50

96.14

105117.74

0.10

362.07

123.94

2026.31

29.10

18.20

31.50

AUROPHARMA

1686.00

26.13

97008.71

0.24

1032.03

25.22

9150.35

17.44

12.76

20.54

LUPIN

2112.00

17.47

96574.55

0.85

1416.98

16.01

8276.89

34.28

28.86

29.59

DRREDDY

1151.50

29.83

96113.39

0.69

435.60

-69.10

8099.80

-5.21

13.75

10.63

MANKIND

2305.85

46.63

95242.00

0.04

574.09

29.12

4030.59

12.89

13.24

26.30

GLENMARK

2477.35

38.89

69916.93

0.10

482.83

927.88

4018.48

31.35

20.35

20.03

GUFICBIO

439.55

60.01

4407.92

0.02

22.31

70.72

260.82

16.58

12.56

17.87

Sep 2023

Dec 2023

Mar 2024

Jun 2024

Sep 2024

Dec 2024

Mar 2025

Jun 2025

Sep 2025

Dec 2025

Mar 2026

Jun 2026

215

202

195

203

204

208

205

224

237

231

252

261

176

165

161

167

166

174

179

190

199

198

205

231

Operating Profit

OPM %

18.32%

18.07%

17.55%

17.64%

18.91%

16.32%

12.86%

14.88%

15.96%

14.25%

18.75%

11.34%

-1

Interest

Depreciation

Profit before Tax

Tax %

25.01%

24.70%

26.07%

25.79%

25.61%

26.50%

26.69%

24.32%

25.58%

29.91%

24.35%

25.72%

Net Profit

2.39

2.23

2.00

2.08

2.17

1.93

0.77

1.30

1.68

1.24

2.18

2.22

Mar 2024

Mar 2025

Mar 2026

TTM

807

820

944

981

659

684

793

833

Operating Profit

147

136

151

148

OPM %

18.26%

16.60%

16.03%

15.05%

Interest

Depreciation

Profit before Tax

116

Tax %

25.53%

26.02%

25.81%

26.04%

Net Profit

EPS

8.59

6.95

6.40

—

Dividend Payout %

1.16%

1.44%

1.56%

—

Mar 2024

Mar 2025

Mar 2026

Equity Capital

523

591

655

313

310

379

Trade Payables

166

159

199

100

Total Liabilities

1,093

1,169

1,342

159

506

491

Capital Work in Progress

307

200

217

324

330

315

297

Cash & Bank

129

Total Assets

1,093

1,169

1,342

Mar 2024

Mar 2025

Mar 2026

-7

123

Cash from Investing

-102

-71

-31

Cash from Financing

-37

-27

Mar 2024

Mar 2025

Mar 2026

Jun 2024

Sep 2024

Dec 2024

Mar 2025

Jun 2025

Sep 2025

Dec 2025

Mar 2026

Jun 2026

72.50

72.51

72.52

72.50

0.23

0.30

0.31

0.32

0.33

0.44

0.42

0.47

2.38

2.51

2.99

3.39

3.38

3.66

3.74

3.83

3.67

Government

0.00

24.88

24.74

24.21

23.79

23.78

23.51

23.32

23.25

23.36

Gufic Biosciences Ltd.

AI Sector View

Peer comparison

Quarterly Results

Profit & Loss

Balance Sheet

Corporate actions

Cash Flows

Ratios

Shareholding Pattern

Documents

News

Sign in to Chat with AI

Gufic Biosciences Ltd.

AI Sector View

Peer comparison

Quarterly Results

Profit & Loss

Balance Sheet

Corporate actions

Cash Flows

Ratios

Shareholding Pattern

Documents

News

Sign in to Chat with AI